The Global report “Cell Culture Market in terms of revenue was estimated to be worth $27.9 billion in 2023 and is poised to reach $51.3 billion by 2028, growing at a CAGR of 12.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by government support and funding for cell-based research and emerging cell culture technologies for cell-based vaccines. Further, the demand for 3D over 2D cell cultures is creating opportunities the growth of this market.
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559
Browse in-depth TOC on “Cell Culture Market”
692 – Tables
42 – Figures
556 – Pages
Key Market Players:
The global cell culture market is a consolidated market, with Thermo Fisher Scientific (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (US) together accounting for ~70–75% of the global market.
Cell Culture Market Dynamics:
Drivers:
- Government support and funding for cell-based research
- Emerging cell culture technologies for cell-based vaccines
- Growing popularity of monoclonal antibodies
- Adoption of single-use technologies
- Growing focus on product development
- Growth in cell and gene therapies and stem cell research
- Incidence of infectious diseases
Restraints:
- High cost of cell biology research
- Limitations in producing high-density cell cultures
Opportunities:
- Demand for 3D over 2D cell cultures
- Growth hotspots in emerging economies
Challenges:
- Disposal of plastic consumables
Request Free Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=559
The equipment segment accounted for the second largest share, by product in the the cell culture market in 2022.
Based on equipment, the cell culture market is segmented into supporting equipment, bioreactors, and storage equipment. Cell culture involves the extensive use of laboratory equipment such as bioreactors, storage equipment, and cell culture-supporting equipment. The growing awareness about the benefits of cell culture-based vaccines (coupled with the growing regulatory approval for these products), increasing production of mAbs, and the introduction of technologically advanced products for high-demand applications (such as cell & gene therapy and regenerative medicine) are the key factors driving the growth of the cell culture equipment market.
The monoclonal antibody production segment accounted for the largest share of the biopharmaceutical production segment in the cell culture market in 2022.
Based on biopharmaceutical production, the cell culture market is categorized into monoclonal antibody production, vaccine production, and other therapeutic protein production. Monoclonal antibodies are multifunctional components of the immune system that fight infections. Most antibodies generated as a natural response are polyclonal, which means they are produced by several B lymphocytes. Monoclonal antibodies, on the contrary, are produced in laboratories and can bind to single specific targets in the body, such as antigens on the surface of certain cancer cells.
The North America region catered the largest share of the cell culture market in 2022.
The growing regulatory approvals for and awareness of cell culture-based vaccines, rising investments in biopharmaceutical R&D coupled with various initiatives from the leading companies, and conferences and symposia that create awareness of the latest cell culture trends are the key factors driving the growth of the cell culture market in North America. Biopharmaceutical companies in North America focus on R&D activities to develop and commercialize novel drugs and therapies. Additionally, various initiatives from leading companies have accelerated growth in North America.
Recent Developments
- In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the US.
- In October 2022, Cytiva acquired Cevec Pharmaceuticals GmbH, which is expected to strengthen Cytiva’s leading position in biomanufacturing solutions.
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=559
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
